HSPA5 and primary cutaneous T-cell non-Hodgkin lymphoma: Our work offers new insight into the control of the Th2-dominant immunosuppressive effects of CTCL and suggests that selective HSPA5/6 inhibitors could be effective targeted therapies for the treatment of CTCL.